The certification follows an inspection of the company’s Plant III facility conducted from April 22, 2026, to April 27, 2026. The company said the certification confirms that the facility complies with Good Manufacturing Practice requirements referred to in the EC Directive.
Aditi Panandikar, Managing Director of Indoco Remedies Ltd, said, “The EU GMP certification for our formulations manufacturing plant is a testament to our commitment to delivering high-quality products to patients across the globe.”
Also Read: Indoco Remedies shares gain over 8.5% post USFDA approval for Lacosamide oral solutionFourth Quarter Results
The pharmaceutical company posted a net loss of ₹22 crore for the fourth quarter, compared with a loss of ₹40 crore in the corresponding period last year. Revenue for the quarter rose 22% year-on-year to ₹476 crore from ₹390 crore earlier.
Operationally, the company reported EBITDA of ₹50.2 crore, a notable turnaround from an EBITDA loss of ₹1 crore in the year-ago quarter. EBITDA margin stood at 10.6%, reflecting improved operating leverage and better business traction across key segments.
For the full financial year FY26, the company reported revenue of ₹1,633.5 crore, compared with ₹1,494.8 crore in the previous year. EBITDA margin for the year improved to 9.6%, with EBITDA at ₹157.2 crore versus ₹128 crore in the previous financial year.
Also Read: Indoco Remedies okays ₹110-cr slump sale of ophthalmic biz to Sunways India
The board has recommended a dividend of ₹0.20 per equity share of face value ₹2 for FY26, subject to shareholder approval at the company’s upcoming annual general meeting.
On Wednesday (May 27), shares of Indoco Remedies Ltd ended at ₹202.90, up by ₹9.05, or 4.67%, on the BSE.
(Edited by : Jomy Jos Pullokaran)
